Seamless Therapeutics

About Seamless Therapeutics

Seamless Therapeutics is a pioneering startup in the field of gene editing, focused on unlocking the full potential of recombinases—specialized enzymes that can precisely modify DNA. The company operates in the biotechnology and life sciences market, aiming to develop innovative treatments for a wide range of serious diseases by reprogramming these enzymes to repair faulty genes.

The primary clients of Seamless Therapeutics include pharmaceutical companies, research institutions, and healthcare providers who are looking for advanced gene editing solutions to treat genetic disorders. By leveraging its proprietary technology platform, Seamless Therapeutics is building a pipeline of disease-modifying product candidates that can address various medical conditions, thereby expanding the therapeutic potential of gene editing.

Seamless Therapeutics follows a business-to-business (B2B) model. It generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its proprietary gene editing therapies. The company has secured significant seed financing, amounting to $12.5 million, from leading life science investors to advance its transformative gene editing platform.

The management team, led by co-founders Anne Kristin Heninger, PhD, and Felix Lansing, PhD, along with VP of Business Development Arturo Urrios, PhD, MBA, brings a wealth of experience and a shared vision to revolutionize the gene editing landscape. The company also benefits from the guidance of an experienced board and advisors, including Prof. Frank Buchholz and Karl PhD.

Seamless Therapeutics fosters a dynamic and collaborative work environment, encouraging creativity, leadership, and teamwork. The company is always on the lookout for dedicated and visionary employees to join its mission of transforming gene editing.